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Background: Capsule and pneumolysin (PLY) are two major virulence factors of Streptococcus pneumoniae. S.
pneumoniae is one of the leading causes of bacterial endophthalmitis. The aim of this study is to determine
whether passive immunization with the 23-valent pneumococcal polysaccharide vaccine (PneumovaxW 23; PPSV23)
or PLY protects against pneumococcal endophthalmitis.
Methods: New Zealand white rabbits were passively immunized with antiserum to PLY, PPSV23, a mixture of
PPSV23/PLY, or PBS (mock). Vitreous was infected with a clinical strain of S. pneumoniae. In a separate group of
experiments, vancomycin was injected 4 hours post-infection (PI) for each passively immunized group. Severity of
infection, bacterial recovery, myeloperoxidase (MPO) activity and percent loss of retinal function were determined.
Results: Passive immunization with each antiserum significantly lowered clinical severity compared to mock
immunization (PPSV23 = 9.19, PPSV23/PLY = 10.45, PLY = 8.71, Mock = 16.83; P = 0.0467). A significantly higher bacterial
load was recovered from the vitreous of PLY passively immunized rabbits 24 hours PI (7.87 log10 CFU) compared to
controls (7.10 log10 CFU; P = 0.0134). Retinas from immunized rabbits were more intact. Vitreous of PLY (2.88 MPO untis/
mL) and PPSV23/PLY (2.17) passively immunized rabbits had less MPO activity compared to controls (5.64; P = 0.0480), and
both passive immunizations (PLY = 31.34% loss of retinal function, PPSV23/PLY = 27.44%) helped to significantly preserve
retinal function compared to controls (64.58%; P = 0.0323). When vancomycin was administered 4 hours PI, all eyes were
sterile at 24 hours PI. A significantly lower clinical severity was observed for rabbits administered the combination
immunization (5.29) or PPSV23 (5.29) with vancomycin treatment compared to controls (17.68; P = 0.0469).
Conclusions: Passive immunization with antisera to these antigens is effective in reducing clinical severity of
pneumococcal endophthalmitis in rabbits. Addition of vancomycin to immunization is effective at eliminating the
bacteria.
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Streptococcus pneumoniae (pneumococcus) is a gram-
positive coccus that is a normal resident of the human
nasopharynx. This bacterium is an opportunistic cause of
many human diseases such as bacteremia, meningitis,
otitis media, peritonitis, pneumonia, and sinusitis [1-4].
Likewise, S. pneumoniae has been reported to be a* Correspondence: MMarquart@umc.edu
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reproduction in any medium, provided the orcommon cause of bacterial endophthalmitis, often as a
result of ocular surgery complications [5-7]. One study of
note reported that out of 497 cases of bacterial
endophthalmitis at the Wills Eye Institute from 1989–
2000, S. pneumoniae was one of the top 3 causes of infec-
tion in cases that caused pathology in the first 3 days [8].
Intraocular infection with this bacterium often leads to
blindness or loss of the eye [7,9,10].
One of the major virulence factors of S. pneumoniae is
the polysaccharide capsule [11-16]. There are at least 91
different capsule types of S. pneumoniae, and purifiedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in vaccines for protection against invasive pneumococcal
diseases. Two pneumococcal vaccines are currently licensed
for use in the United States and are based on the polysacchar-
ide capsule, the 13-valent conjugate vaccine (Prevnar 13W;
Pfizer (formerly Wyeth Pharmaceuticals), New York, NY,
USA) and the 23-valent polysaccharide vaccine (PneumovaxW
23; PPSV23;Merck,Whitehouse Station, NJ, USA) [17-19].
PneumovaxW 23 contains purified polysaccharides of
the 23 most commonly found serotypes in pneumococcal
infections (1, 2, 3, 4, 5, 6B, 7 F, 8, 9 N, 9 V, 10A, 11A, 12 F,
14, 15B, 17 F, 18C, 19 F, 19A, 20, 22 F, 23 F, and 33 F;
listed on the drug literature insert). In studies thus far, im-
mune protection has been tested for non-ocular diseases.
A study by Jeurissen et al. [20] elucidated the immune re-
sponse to the polysaccharides allows protection from cer-
tain diseases. Robbins et al. [18] observed 90% protection
from blood isolates and 85% protection from colonization
of normally sterile sites by S. pneumoniae with these sero-
types. Regarding ocular studies, this laboratory previously
showed that capsule is important for pneumococcal
endophthalmitis [21]. The pathogenesis of a parent clinical
isolate and isogenic capsule mutant were compared in a
rabbit endophthalmitis model. Capsule was determined to
be important for infection and retinal damage in this
model. These findings led to the question of whether
PPSV23 could protect the eye from damage observed dur-
ing pneumococcal endophthalmitis.
Another virulence factor of S. pneumoniae is pneumolysin
(PLY), a cholesterol-dependent cytolysin [22]. PLY binds to
cholesterol in the membranes of host cells and forms pores,
often resulting in cell lysis [23-25]. Pure toxin injected into
the vitreous of rabbits shows the same severity of infection as
living pneumococcus injected into the vitreous [26]. PLY
mutants of S. pneumoniae cause less severe pathology than
their parent strains in rabbitmodels [26,27]. A previous study
by this laboratory showed that vaccination with PLY signifi-
cantly lowered pathogenesis caused by pneumococcal
endophthalmitis in a rabbit model at 24 and 48 hours PI.
Vaccination with PLY also significantly lowered retinal dam-
age at 48 hours post-infection (PI) [28]. However, the bacter-
ial load was high in the vitreous and some (albeit much less)
ocular damage still occurred in the immunized animals,
which prompted further investigation. Due to the previous
findings that both capsule and PLY are important in the
pathogenesis of pneumococcal endophthalmitis, the current
study was undertaken to determine whether antisera specific
for pneumococcal capsule, alone or in combination with
PLY-antisera, could provide protection against this disease.
Methods
Model
Specific pathogen-free (SPF) New Zealand white rabbits
(Harlan Sprague Dawley, Inc, Oxford, Michigan, USA)were used in these studies and maintained according to
the ARVO Statement for the Use of Animals in Ophthal-
mic and Vision Research and the Institutional Animal
Care and Use Committee of the University of Mississippi
Medical Center.Antiserum preparation
Antisera were produced by active primary immunization
of rabbits as previously described [28,29]. The immuno-
gens used in this study were PPSV23, PPSV23/ΨPLY (a
form of recombinant PLY with a Trp433Phe substitution
that results in retention of only 1% cytolytic activity
[30]), or PBS (“mock”). We previously reported the effect
of active immunization with ΨPLY and vitreal challenge
with a clinical ocular strain of S. pneumoniae [28]; there-
fore, this experimental group (ΨPLY active immunization)
was not included in the current study. Each rabbit was
bled before the first immunization and one week after
each boost for the isolation of serum.
Serum anti-PPSV23, anti-PLY, and anti-19 F IgG titers
were determined by ELISA [31]. As a control for the pos-
sible production of antibodies against the histidine tag of
ΨPLY, ELISA plates were coated with an unrelated protein
containing the same type of histidine tag to determine IgG
titers to the histidine tag in the rabbit serum. Since
PPSV23 is contaminated with up to 5% cell wall, serum
was adsorbed with purified cell wall polysaccharide before
performing the ELISA [32]. Plates were coated with
PPSV23 for determination of vaccine-specific IgG titer,
ΨPLY for the determination of PLY-specific IgG titer, or
19 F purified polysaccharide to determine the titer specific
to the clinical isolate capsule type. Each titer was defined
as the highest dilution which was double the background
absorbance (A410).Passive immunization
For passive immunization studies, rabbits were adminis-
tered 1 mL of antiserum against PPSV23, PPSV23/PLY,
PLY, or mock antiserum in the ear vein at the same time
as infection. Mock antiserum had no titer. All other sera,
after pre-adsorption with cell-wall polysaccharide where
applicable, had specific titers ≥ 12,800.Bacterial growth
S. pneumoniae E335, a serotype 19 F clinical endo-
phthalmitis strain, was provided by Regis Kowalski
(Charles T. Campbell Eye Microbiology Lab, Pittsburgh,
Pennsylvania, USA) and was grown to approximately 108
colony-forming units (CFU) per mL as previously de-
scribed [28]. Accuracy of the bacterial CFU was verified
by plate counts of serial dilutions.
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Each rabbit was anesthetized and infected intravitreously
with approximately 102 CFU in 10 μL as previously de-
scribed [28].
Vancomycin treatment
At 4 hours PI, 100 μL of vitreous was aspirated from
passively immunized rabbits using a 30-gauge needle.
Each eye was then injected with 100 uL of vancomycin
(1 mg/ 0.1 mL; Sigma-Aldrich) using a 30-gauge needle.
Slit lamp examination (SLE)
SLE for endophthalmitis was previously described [33]. In
short, eight parameters were used for determining the se-
verity of endophthalmitis. Each parameter was given a
grade from 0 (no pathogenesis) to 4 (maximal pathogen-
esis), resulting in a total score with a theoretical maximum
of 32.
CFU recovery
Vitreous was removed from each eye at 24 hours PI for
all experiments using a 22-gauge needle. The vitreous
samples were serially diluted, cultured in triplicate on
blood agar, and incubated in 5% CO2 at 37°C overnight
for quantitation of log10 CFU per mL recovered.
Whole blood survival assay
A bacterial survival assay was performed on blood from
the rabbits that were actively immunized to generate the
antisera used in the passive immunization experiments
using a previously published technique [34]. In short,
1 mL of whole blood from PPSV23, PPSV23/PLY, or
mock immunized rabbits was mixed with 100 CFU of S.
pneumoniae in Todd Hewitt broth containing 0.5% yeast
extract (THY). Each sample was placed in a shaker incu-
bator at 37°C for 3 hours, serially diluted, plated in trip-
licate, and incubated overnight to determine bacterial
survival.
Histopathology
Whole eyes were removed, and histologic sectioning
and staining were performed (Excalibur Pathology, Inc.,
Moore, OK). Hematoxylin and eosin staining was used
to stain eosinophils and general ocular architecture.
Myeloperoxidase (MPO) activity assay
The MPO activity of neutrophils in infected vitreous of
passively immunized rabbits was determined using a col-
orimetric assay as described previously [35]. Uninfected
vitreous served as a background control, and purified
MPO (Sigma-Aldrich) served as a positive control. MPO
activity was expressed as MPO units per mL.Vitreal Immunoglobulin G (IgG)
The presence of PPSV23 or PLY specific IgG in the vitre-
ous was determined using ELISA [32]. Samples of vitreous
were taken 24 hours PI. ELISA plates were coated with
either PPSV23 or PLY. A positive titer was defined as pro-
ducing at least double the background absorbance (A410).
Electroretinography (ERG)
ERG was used to quantify the retinal response, as previ-
ously described [21]. Percent loss of retinal function was
calculated as {[1 – (experimental B-wave amplitude /
baseline B-wave amplitude)] × 100}. ERG results with no
demonstrable waveform were assigned a value of 0.00 μV.
Statistics
Clinical SLE scores and bacterial CFU data were ana-
lyzed as dependent variables using a two level factorial
model in the analysis of variance. The main factor was
treatment (mock, PPSV23 or PPSV23/PLY). The model
was analyzed as a repeated measures model where
within subject correlation (eyes within rabbit) was taken
into account [36]. The error term was based on two rep-
lications of each of the experiments. Mean values for the
interaction of time by treatment were separated in post-
hoc testing using a method of simulation for alpha level
adjustment for multiple comparisons [37]. Whole blood
survival data were analyzed using the non-parametric
Mann–Whitney U test [38]. The alpha level for all hy-
pothesis tests in all statistical procedures was pre-set at
0.05. All data analysis and manipulation was carried out
using the Statistical Analysis System (SAS Institute,
Cary, NC, USA). All p values stated in results and fig-
ures are adjusted p values from post-hoc t tests follow-
ing a significant overall F test in the ANOVA models.
Results
Antibody titers
Antisera to PPSV23 had specific anti-PPSV23 IgG ti-
ters ≥ 12,800. PLY-specific serum IgG titers were ≥
51,200. Antisera to PPSV23/PLY had anti-PPSV23 IgG
titers ≥ 12,800 and anti-PLY IgG titers ≥ 51,200. No IgG
titer was observed for control (mock) antisera (< 100). A
low titer (~ 800) for the histidine tag of the unrelated re-
combinant protein was observed in antisera to PLY and
PPSV23/PLY. Anti-19 F IgG titers were between 6,400
and 12,800 for PPSV23/PLY antisera and 1,600 and
12,800 for PPSV23 antisera.
Endophthalmitis severity in immunized rabbits
Passive administration of antisera from all experimental
groups was able to reduce SLE scores significantly as com-
pared to rabbits administered mock serum at 24 hours
PI (P = 0.0467; Figure 1, Table 1). None of the passive
immunization experimental groups (PPSV23, PPSV23/PLY,
Figure 1 Representative eyes of PPSV23, PPSV23/PLY, PLY, or
mock passively immunized rabbits at 24 hours PI.
Table 1 Mean SLE scores* and percent loss of retinal
function* of passively immunized rabbits
SLE scores % Loss retinal function
24 hours PI 24 hours PI
PPSV23 Passive 9.19 ± 1.67+ 40.12 ± 24.26
PPSV23/ΨPLY Passive 10.45 ± 1.67+ 27.44 ± 16.69+
ΨPLY Passive 8.71 ± 1.67+ 31.34 ± 18.34+
Mock Passive 16.83 ± 1.67 64.58 ± 27.15
* ± SEM.
+Significantly lower than Mock.
N = 12 eyes per group for SLE and 6 eyes per group for retinal function.
Table 2 Mean SLE scores* and percent loss of retinal
function* of passively immunized rabbits administered
vancomycin 4 hours post-infection
SLE scores % Loss retinal function
24 hours PI 24 hours PI
PPSV23 Passive 6.00 ± 0.53 5.12 ± 7.56+
PPSV23/ΨPLY Passive 5.09 ± 0.43# 5.29 ± 9.62+
ΨPLY Passive 6.61 ± 0.23 9.07 ± 15.66
Mock Passive 6.92 ± 0.47 17.68 ± 13.36
* ± SEM.
#Significantly lower than PLY and Mock.
+Significantly lower than Mock.
N = 4 eyes per group for SLE and 4 eyes per group for retinal function.
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other in mean SLE scores (P = 0.8846). A more severe infil-
tration of immune cells was observed in the aqueous
humor (Figure 1) and vitreous humor of the mock immu-
nized rabbits as compared to all other passively immunized
groups. Passive immunization experiments were termi-
nated at 24 hours PI because the control rabbits were eu-
thanized due to the severity of the infection. When
vancomycin was injected into the vitreous at 4 hours PI, asignificantly lower severity of infection was observed for
PPSV23/PLY passively immunized rabbits at 24 hours PI
as compared to PLY and mock passively immunized groups
(P = 0.0469; Table 2). The subtle differences between
vancomycin-treated eyes of different groups were not able
to be distinguished by photography (not shown).
CFU recovery
Rabbits that were administered mock antisera had a sig-
nificantly lower mean log10 CFU/mL recovered from the
vitreous than rabbits passively immunized with PLY anti-
sera (P = 0.0134). No significant difference was observed
among any other groups tested at 24 hours PI (P =
0.2681; Table 3). All eyes were sterile at 24 hours PI re-
gardless of immunization when vancomycin was injected
into the vitreous at 4 hours PI.
Whole blood survival assay
Whole blood from PPSV23 actively immunized rabbits was
able to kill bacteria significantly better than whole blood
from mock immunized rabbits (15 ± 5 CFU and 1302 ±
248 CFU, respectively; P = 0.0004; n = 9 and 6; respectively).
Also, whole blood from PPSV23/PLY actively immunized
rabbits was significantly better at killing bacteria than whole
blood from mock immunized rabbits (17 ± 7 CFU and
1,499 ± 100 CFU, respectively; P < 0.0001; n = 9 per group).
No significant difference was observed between PPSV23
and PPSV23/PLYwhole blood (P = 0.8475).
Table 3 Log10 CFU/mL* recovered from vitreous of
passively immunized rabbits
Group n value Log10 CFU/mL
24 hours PI
PPSV23 12 7.54 ± 0.17
PPSV23/ΨPLY 12 7.47 ± 0.17
ΨPLY 12 7.87 ± 0.17+
Mock 12 7.10 ± 0.17
* ± SEM.
+Significantly higher than mock immunized rabbits at same time point.
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Less destruction of the retina was observed in infected
eyes of PLY, PPSV23 and PPSV23/PLY passively immu-
nized rabbits as compared to mock passively immunized
rabbits (Figure 2). The retinas of rabbits passively immu-
nized with PPSV23, PPSV23/PLY, or PLY antibodies
retained much of their cellular layers, whereas the
control retina appeared to be highly disrupted. When
vancomycin was administered 4 hours PI to passively
immunized rabbits, only slight pathology, if any, was ob-
served in retinas for all groups (Figure 3). Slightly more
edema (black arrows) was observed in the retina of
PPSV23, PPSV23/PLY and mock passively (Figure 3A, B,
and D; respectively) immunized rabbits as compared to
PLY passively immunized rabbits or eyes receiving only
vancomycin (Figure 3C and E; respectively).Figure 2 Representative histology showing the retinas of infected eye
passively immunized rabbits 24 hours PI. A-D are 200x and E-H are 100MPO activity assay
MPO activity correlates to the amount of neutrophils
present in a sample. At 24 hours PI, the infected vitreous
of rabbits passively immunized with mock serum had the
highest average MPO activity of all passive immunization
groups. Significantly lower MPO activity was present in the
infected vitreous of rabbits passively immunized with
PPSV23/PLY and PLY antisera compared to the vitreous of
rabbits that were given mock sera (P = 0.0480). No signifi-
cant difference was observed among any other group of
passively immunized rabbits (P = 0.1165; Table 4). Overall,
MPO activity was low or undetectable for all groups re-
ceiving passive immunization combined with administra-
tion of intravitreal vancomycin (P = 0.3359; Table 5).
Vitreal IgG
Anti-PLY IgG was detected in undiluted vitreous of
rabbits passively immunized with PLY or PPSV23/PLY
antiserum. Anti-PPSV23 IgG was not detected in the vit-
reous of rabbits passively immunized with PPSV23 or
PPSV23/PLY antiserum. Neither anti-PLY IgG nor anti-
PPSV23 IgG was detected in the vitreous of mock pas-
sively immunized rabbits (data not shown).
ERG
A significantly lower percent loss of retinal function was
observed in rabbits passively immunized with PLY or
PPSV23/PLY antiserum as compared to mock passively
immunized rabbits at 24 hours PI (P = 0.0323). Passives of PPSV23 (A,E), PPSV23/PLY (B,F), PLY (C,G), or mock (D,H)
0x original magnification.
Figure 3 Representative histology showing the retinas of infected eyes of PPSV23 (A), PPSV23/ΨPLY (B), ΨPLY (C), or mock (D)
passively immunized rabbits 24 hours PI treated with vancomycin at 4 hours PI. (E) Representative retina of uninfected eye treated with
vancomycin at 4 hours PI. A-E are 200x original magnification. Black arrows indicate edema.
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cent loss of retinal function when compared to mock
immunized rabbits at 24 hours PI, although not signifi-
cantly (P = 0.1309). No significant difference was ob-
served among any other treatment groups (P = 0.3163;
Table 1). A significantly lower percent loss of retinal
function was observed for rabbits passively immunized
with PPSV23 and PPSV23/PLY compared to mock pas-
sively immunized rabbits when vancomycin was admin-
istered 4 hours PI (P = 0.0200; Table 2). In the same
treatment group, a lower percent loss of retinal function
was observed for rabbits passively immunized with PLY
antiserum, though not significantly lower than mock
passively immunized rabbits (P = 0.4000). Vancomycin
treatment alone caused a small, but not significant, per-
cent loss of retinal function.
Discussion
Currently, PneumovaxW 23 is used for protection against
pneumonia in adults. The effectiveness of this vaccine
against pneumococcal endophthalmitis has never been
reported. A recent study showed that the pneumococcal
capsule is a virulence factor for endophthalmitis [21].
Since pneumococcal endophthalmitis can result in se-
vere complications such as loss of vision or ocular mor-
bidity [5-7], the possible protective value of the currently
available capsule-based vaccine was investigated. Add-
itionally, PLY has not only been shown to be an import-
ant virulence factor for S. pneumoniae endophthalmitis
[26,27], but has also been shown to be effective as anTable 4 MPO units/mL* recovered from vitreous of
passively immunized rabbits
Passive immunization group 24 hours PI
PPSV23 2.92 ± 1.04
PPSV23/ΨPLY 2.17 ± 0.47+
ΨPLY 2.88 ± 0.66+
Mock 5.64 ± 1.23
* ± SEM.
+Significantly lower than mock passively immunized rabbits.
N = 7 eyes per group.immunogen for the active immunization of rabbits and
subsequent vitreal challenge with S. pneumoniae [28].
Therefore, the possibility of using a combination of anti-
sera to both capsule and PLY was investigated to deter-
mine whether additive or enhanced protection could be
achieved by passive administration.
For the current study, a capsule type 19 F strain was
used for infection because capsule type 19 F is included
in the polyvalent pneumococcal vaccine. Whereas whole
blood from PPSV23 and PPSV23/PLY actively immu-
nized rabbits was able to kill S. pneumoniae in vitro, pas-
sive administration of antisera from these rabbits did not
provide a bacterial clearing effect for the vitreous of the
recipient rabbits. We also observed a lack of bacterial
clearance in the infected vitreous of the actively immu-
nized animals despite significant protection of the ret-
inas from pathology (data not shown). One explanation
could be that complement is involved in the clearing of
bacteria. The interior of the eye is an immune privileged
area. Far lower amounts of complement proteins are
found inside the eye, even when the eye is inflamed due
to infection [39,40]. Also, membrane-bound regulatory
proteins in the eye block deposition of C3b (deposition
involved in opsonophagocytosis of gram-positive bac-
teria) so that the complement pathway will not destroy
self-tissue of the eye. These regulatory complexes are not
present in the blood, so components of whole blood were
able to opsonize the bacteria [41]. Alternatively, the anti-
bodies administered through passive immunization could
have neutralized the binding of bacteria to the tissueTable 5 MPO units/mL* recovered from vitreous of
passively immunized rabbits administered vancomycin 4
hours post-infection
Passive immunization group 24 hours PI
PPSV23 0.00 ± 0.00
PPSV23/ΨPLY 0.09 ± 0.09
ΨPLY 0.00 ± 0.00
Mock 1.33 ± 1.33
* ± SEM.
N = 4 eyes per group.
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response.
Another explanation for the differences observed in
bacterial recovery in vivo compared to bacterial killing
in vitro is due to disparities in capsule type antibodies.
One study showed that the antibody titers to PPSV23
vaccination are not equal for each capsule type [42].
Also, an immortalized cell line producing monoclonal
antibody to PPSV23 was shown to only produce anti-
bodies specific to one capsule type included in the vac-
cine (capsule type 8), but not the 13 other capsule types
tested [43]. The capsule type of the bacteria may play a
role in how well the bacteria are cleared.
It is of note that less neutrophil activity was observed
in the infected vitreous of rabbits passively immunized
with PPSV23/PLY or PLY compared to rabbits passively
immunized with mock serum. It is not surprising that
these immunized animals had higher bacterial loads re-
covered from the vitreous than mock-immunized ani-
mals since fewer neutrophils were present to kill the
bacteria. Since anti-PLY IgG but not anti-PPSV23 IgG
was detected in the vitreous of the immunized rabbits, it
is a likelihood that anti-PLY antibodies may account for
the reduction in neutrophil infiltration and thus an in-
crease in bacterial loads.
The lack of bacterial clearance could be circumvented
by administration of an antibiotic, which is normally given
to patients affected by bacterial endophthalmitis. Vanco-
mycin is a commonly used treatment for gram-positive
bacterial endophthalmitis [9,44]. Since administration of
passive antibodies was able to protect against retinal dam-
age, we decided to test whether treatment with vanco-
mycin could help clear the bacteria from the vitreous of
passively immunized rabbits. In this study, we found that
treating the pneumococcal endophthalmitis infection at 4 -
hours PI, when inflammation was beginning to be ob-
served, completely sterilized the eye. This treatment time
was chosen in an attempt to provide some clinical rele-
vance, that is, a time when inflammation was observable
and treatment options might be sought. Even with early
vancomycin treatment and complete sterility of the eye,
immunization was still helpful in significantly lowering
the percent loss of retinal function and preserving some of
the retinal architecture for rabbits passively immunized
with PPSV23 or PPSV23/PLY antiserum.
Immunization strategies to provide some protection
against pneumococcal endophthalmitis could be useful
in clinical situations. Since ocular surgery, especially
cataract surgery, has been documented to be a major
cause of bacterial endophthalmitis [5,6,45], and since S.
pneumoniae is commonly isolated as the cause of post-
surgical endophthalmitis [5-7], passive administration of
antibodies to capsule and/or PLY in addition to prophy-
lactic or postoperative antibiotics could be attempted toprevent complications. In the same way, those patients
that have already been administered a vaccine consisting
of capsule and/or PLY for the prevention of invasive
pneumococcal diseases may receive additional benefit of
protection from retinal damage during endophthalmitis,
especially if the treatment includes antibiotics that are
effective at sterilizing the eye [46]. These possibilities
would need to be examined in humans, however, to de-
termine their plausibility.
Conclusions
Taken together, the results indicate that passive immu-
nization with PPSV23 and/or PLY is significantly more
effective at preserving ocular integrity during pneumo-
coccal endophthalmitis than negative controls. It appears
that retinal function fared better in rabbits that were ad-
ministered PLY or PPSV23/PLY antisera than in those
given PPSV23 antisera, although there was some preser-
vation of function in the PPSV23 group. Immunization
alone was not able to reduce the bacterial burden in the
vitreous, however, the addition of vancomycin provided
a synergistic effect of sterilizing the eye while the com-
bination PPSV23/PLY antiserum reduced clinical severity
and loss of retinal function.
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